Clinical Trials Logo

Clinical Trial Summary

This study is to assess the MTD and RP2D of NM6603 in adult patients with advanced solid tumors.


Clinical Trial Description

This is a Phase 1, first-in-human, multicenter, open label, 3+3 dose escalation study designed to evaluate the safety profile, the maximum tolerated dose (MTD), the recommended Phase 2 dose (RP2D), the pharmacokinetic and the preliminary antitumor activity of NM6603 in patients with advanced solid tumors. The study has two parts. In Part 1, NM6603 will be administered once daily. In Part 2, NM6603 will be administered twice daily to explore the effect of twice daily dosing on the pharmacokinetic, safety and tolerability, and anti-tumor activity profile of NM6603, ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06046066
Study type Interventional
Source NucMito Pharmaceuticals Co. Ltd.
Contact COO
Phone +86-15306980619
Email ClinicalDevelopment@nucmito.com
Status Recruiting
Phase Phase 1
Start date August 31, 2023
Completion date July 31, 2026

See also
  Status Clinical Trial Phase
Completed NCT01127711 - Cohort of Swedish Men N/A
Recruiting NCT05299710 - Ovarian Tissue Cryopreservation in Pre-Pubertal (OTC-Pre Pubertal)
Completed NCT01295658 - Cancer Survivor Registry: The Breast Cancer M.A.P. (Mind Affects the Physical) Project
Completed NCT01127698 - Swedish Mammography Cohort N/A
Completed NCT02734303 - Study to Estimate Radiation Doses and Cancer Risks From Radioactive Fallout From the Trinity Nuclear Test
Completed NCT01646437 - The International Polycap Study 3 (TIPS-3) Phase 3
Completed NCT01441674 - Animal Assisted Therapy in a Pediatric Setting Phase 1/Phase 2
Completed NCT04198896 - The Sakakibara Health Integrative Profile of Atherosclerotic-Carcinogenesis Hypothesis (SHIP-AC)
Completed NCT01185470 - The Clinical Evaluation of Implantable Pump System For Safety And Delivery Accuracy In Patients Requiring Intrathecal Administration Of Morphine Sulfate For Chronic Pain Phase 2/Phase 3
Completed NCT00484016 - Drug Delivery and Toxicities of Adjuvant Chemotherapy in Resected NCSLC N/A
Completed NCT03378895 - CEPPPIA Pilot. Experimental Center of Participative and Individualized Predictive Prevention in Auvergne N/A